Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where efficacy cannot be ascertained in a short period of time, it is common to divide the study in two stages: (i) a first stage in which dose is escalated based only on toxicity data and we look for the maximum tolerated dose (MTD) set and (ii) a second stage in which we search for the most efficacious dose within the MTD set. Current available approaches in the area of continuous dose levels involve fixing the MTD after stage I and discarding all collected stage I efficacy data. However, this methodology is clearly inefficient when there is a unique patient population present across stages. In this article, we propose a two-stage design for the combination of two cytotoxic agents assuming a single patient population across the entire study. In stage I, conditional escalation with overdose control is used to allocate successive cohorts of patients. In stage II, we employ an adaptive randomisation approach to allocate patients to drug combinations along the estimated MTD curve, which is constantly updated. The proposed methodology is assessed with extensive simulations in the context of a real case study.

Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials / Jiménez, José L.; Tighiouart, Mourad. - In: JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS. - ISSN 0035-9254. - 71:5(2022), pp. 1996-2013. [10.1111/rssc.12598]

Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials

José L. Jiménez;
2022

Abstract

Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where efficacy cannot be ascertained in a short period of time, it is common to divide the study in two stages: (i) a first stage in which dose is escalated based only on toxicity data and we look for the maximum tolerated dose (MTD) set and (ii) a second stage in which we search for the most efficacious dose within the MTD set. Current available approaches in the area of continuous dose levels involve fixing the MTD after stage I and discarding all collected stage I efficacy data. However, this methodology is clearly inefficient when there is a unique patient population present across stages. In this article, we propose a two-stage design for the combination of two cytotoxic agents assuming a single patient population across the entire study. In stage I, conditional escalation with overdose control is used to allocate successive cohorts of patients. In stage II, we employ an adaptive randomisation approach to allocate patients to drug combinations along the estimated MTD curve, which is constantly updated. The proposed methodology is assessed with extensive simulations in the context of a real case study.
File in questo prodotto:
File Dimensione Formato  
Jimenez and Tighiouart 2022 JRSS C preprint.pdf

Open Access dal 27/10/2023

Descrizione: Article preprint
Tipologia: 2. Post-print / Author's Accepted Manuscript
Licenza: PUBBLICO - Tutti i diritti riservati
Dimensione 542.12 kB
Formato Adobe PDF
542.12 kB Adobe PDF Visualizza/Apri
Combining cytotoxic agents with continuous dose levels in seamless phase I‐II clinical trials.pdf

non disponibili

Tipologia: 2a Post-print versione editoriale / Version of Record
Licenza: Non Pubblico - Accesso privato/ristretto
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2973291